The WRAP Study aims to expand and understand the safety and efficacy data on the WRAPSODY Endoprosthesis System in a real-world population.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Subject provides written informed consent for study participation.
2. Subject is male or female, with an age ≥ 18 years at date of enrollment.
3. Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 24 months.
4. Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon
5. The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session.
6. Subject has stenosis or occlusion within the dialysis outflow circuit of an arteriovenous (AV) fistula or AV graft and is treated with WRAPSODY Endoprosthesis System in accordance with device instructions for use.
Exclusion Criteria:
1. Subject has a planned surgical revision of access site.
2. Subject has a known or suspected infection of the hemodialysis access site, systemic infection and/or septicemia.
3. Subject has an uncorrectable coagulation disorder.
4. Known hypersensitivity to nickel titanium alloy.
5. Subject's hemodialysis access is anticipated to be abandoned within 6 months.
6. Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure.
7. Full expansion of a Percutaneous Transluminal Angioplasty (PTA) balloon cannot be achieved during predilatation.
8. Device would be placed in the Superior Vena Cava
9. Any inflow or outflow lesion that could jeopardize patency access long-term beyond the target treatment area.
Primary outcome measure(s)
Proportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint) — 6 months Proportion of subjects with Target Lesion Primary Patency (TLPP) at 6 Months. TLPP is defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or target lesion thrombosis measured through 6 months post-procedure, which is the time interval of uninterrupted patency after study procedure to the next intervention performed on the target lesion or uncorrectable target lesion occlusion.
Proportion of subjects without any localized or systemic safety events (Primary Safety Endpoint) — 30 days Proportion of subjects without any localized or systemic safety events through 30 days post-index procedure that affect the access or venous outflow circuit and resulted in reintervention, hospitalization, or death (not including stenosis or thrombosis).
Trial sites (35)
Facility
City
Region
Status
Monash Health
Clayton
Australia
Liverpool Hospital
Liverpool
Australia
Fiona Stanley Hospital
Murdoch
Australia
Sir Charles Gairdner Hospital
Nedlands
Australia
Princess Alexandra Hospital
Woolloongabba
Australia
Hospital Felicio Rocho
Belo Horizonte
Brazil
Afya Hospital
Brasília
Brazil
Hospital Santa Lucia
Brasília
Brazil
Hospital Vera Cruz
Campinas
Brazil
Instituto Pro Renal
Curitiba
Brazil
Complexo Hospitalar de Niterói
Niterói
Brazil
Parana Medical Research Center
Paranã
Brazil
Real Hospital Português de Beneficência em Pernambuco
Recife
Brazil
Impar Servicos Hospitalares S/A - Hospital Sao Lucas
Rio de Janeiro
Brazil
Rio de Janeiro State University
Rio de Janeiro
Brazil
Hospital Da Bahia
Salvador
Brazil
Centro Internacional de Pesquisa do Hospital Alemão Oswaldo Cruz
São Paulo
Brazil
Hospital Santa Rita de Cassia
São Paulo
Brazil
Instituto Dante Pazzanese de Cardiologia
São Paulo
Brazil
Protestant Hospital Queen Elisabeth Herzberge
Berlin
Germany
University of Cologne
Cologne
Germany
The General University Hospital of Patras
Rio
Greece
Shaare Zedek Medical Center
Jerusalem
Israel
Maastricht UMC+
Maastricht
Netherlands
Te Toka Tumai Auckland
Auckland
New Zealand
Te Whatu Ora Health NZ Waitemata
Auckland
New Zealand
Te Whatu Ora Health NZ Waitaha Canterbury
Christchurch
New Zealand
Te Whatu Ora Health New Zealand Waitemata
Hamilton
New Zealand
CHUC - Centro Hospitalar e Universitário De Coimbra
Coimbra
Portugal
Belfast City Hospital, Belfast Health and Social Care Trust
Belfast
United Kingdom
Queen Elizabeth Hospital, University Hospital Birmingham
Birmingham
United Kingdom
King's College Hospital, NHS Foundation Trust
London
United Kingdom
Royal London Hospital, Barts Health NHS Trust
London
United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.